The Hidden Costs of Safer Supply: When Prescribed Opioids Reach the Streets

Elderly person pouring a white prescription tablet from a prescription bottle into their hand, accompanying discussion on safer supply programmes.

About a decade ago, doctors in Ontario began prescribing hydromorphone to people with substance use disorders. The thinking was straightforward. Give patients a pharmaceutical opioid to take home, and they might steer clear of street drugs such as fentanyl. Street fentanyl is often mixed with other substances and can be unpredictable. Ten years on, safer supply programmes are under fresh scrutiny, and the unintended costs are getting harder to ignore.

Ontario’s medical regulator is now stepping in to tighten safer supply programmes. Meanwhile, critics ask whether the approach has fed the very problem it was meant to solve.

Regulators move to tighten the rules

The College of Physicians and Surgeons of Ontario planned to vote on 13 October on stricter guardrails for prescription opioid programmes. It had already acted once. In May, the College began requiring doctors to see patients in person and offer other addiction medicines before starting them on prescription opioids. Doctors must also assess these patients in person every three months.

The new proposal for safer supply programmes goes further. Patients would have to take their pills at the pharmacy or clinic. Prescriptions for drug users would carry an eight week limit. In person clinical assessments would happen once a month. British Columbia has already travelled down a similar road. Last year, the province reined in its programme after leaked documents showed that people were trafficking a significant portion of the pills. Patients there now take their medication in front of a medical professional or pharmacist. In Ontario, by contrast, doctors regularly let patients take large amounts of pills off site.

When prescribed pills reach the street

A recent Globe and Mail investigation found that hydromorphone is not strong enough to hold cravings at bay for many users. So they sell it on the black market and use the money to buy fentanyl. All too often, those pills land in the hands of young people looking for a cheap high.

That is where safer supply programmes can backfire. Some buyers wrongly assume that a pharmacy supplied drug must be safe. It is not. Even small amounts can make a person stop breathing, and teenagers or others with no prior opioid tolerance face the greatest risk of accidental overdose or addiction. Some users chasing a stronger high go on to fentanyl themselves. Rather than easing addiction, the pills give fentanyl users an easy way to fund their habit while pushing cheap opioids into the wider community.

Health risks that go beyond diversion

Diversion is only part of the story. Public health researchers and other critics point to more risks for people enrolled in these programmes. Many recipients keep using toxic street drugs alongside their prescribed pills, which can compound sedation and raise the chance of an overdose. Others crush and inject tablets made for swallowing. According to critics, that practice can cause vascular damage, serious infections and endocarditis, an infection of the heart valves.

The effects spill into communities too. Cheap or free pills can push down black market prices. Buyers can also trade them for more potent drugs such as illicit fentanyl. Local businesses and residents have also raised worries about discarded drug paraphernalia and public safety near distribution sites and clinics.

Commercial incentives add another layer. Hamilton addictions doctor Lori Regenstreif says some pharmacies have built lucrative businesses by having doctors hand out prescriptions online to walk in patients. Premier Doug Ford has been vocal about moving away from safe consumption sites and towards recovery focused treatment. Yet pharmaceutical opioids have drawn far less attention. Individual doctors prescribe them, and specialty pharmacies promote them.

Why safer supply programmes need a recovery goal

Supporters hoped the approach would cut overdose deaths. Critics reply that the rollout has sometimes moved faster than the long term clinical data. Nobody has yet proved it lowers deaths everywhere without creating new dependency. That gap in the evidence matters.

The Globe and Mail’s editorial board argues that prescriptions should sit inside long term treatment plans with recovery as the goal. It adds that only doctors who specialise in addictions should offer them. Methadone and suboxone have a role, but they work best within a comprehensive plan. That plan should help patients work through trauma, reconnect with loved ones and find stable housing and employment.

History offers a warning. The opioid crisis took off when Purdue Pharma flooded the market with addictive pills. Purdue also brought hydromorphone to Canada under the name Dilaudid. Flooding communities with more opioids will not end the crisis. Expanding treatment options gives people a real chance to get clean and rebuild their lives. That is the better path for safer supply programmes and for the communities around them.

Source: dbrecoveryresources

Leave a Reply

Your email address will not be published.